JPH0541605B2 - - Google Patents
Info
- Publication number
- JPH0541605B2 JPH0541605B2 JP30359889A JP30359889A JPH0541605B2 JP H0541605 B2 JPH0541605 B2 JP H0541605B2 JP 30359889 A JP30359889 A JP 30359889A JP 30359889 A JP30359889 A JP 30359889A JP H0541605 B2 JPH0541605 B2 JP H0541605B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- improving agent
- metabolism improving
- sodium salt
- brain metabolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 20
- 159000000000 sodium salts Chemical class 0.000 claims description 18
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 16
- 229960003964 deoxycholic acid Drugs 0.000 claims description 16
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 14
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 14
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 14
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 12
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229940099347 glycocholic acid Drugs 0.000 claims description 12
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 11
- 230000004060 metabolic process Effects 0.000 claims description 11
- 235000019416 cholic acid Nutrition 0.000 description 18
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 16
- 239000002812 cholic acid derivative Substances 0.000 description 14
- 150000001842 cholic acids Chemical class 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229960001340 histamine Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000000941 bile Anatomy 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 4
- 239000004380 Cholic acid Substances 0.000 description 4
- 210000001841 basilar artery Anatomy 0.000 description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 4
- 229960002471 cholic acid Drugs 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- -1 glycocholic acid Cholic acids Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30359889A JPH03161442A (ja) | 1989-11-21 | 1989-11-21 | コール酸又はそのナトリウム塩からなる脳代謝改善剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30359889A JPH03161442A (ja) | 1989-11-21 | 1989-11-21 | コール酸又はそのナトリウム塩からなる脳代謝改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03161442A JPH03161442A (ja) | 1991-07-11 |
| JPH0541605B2 true JPH0541605B2 (enrdf_load_stackoverflow) | 1993-06-24 |
Family
ID=17922928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30359889A Granted JPH03161442A (ja) | 1989-11-21 | 1989-11-21 | コール酸又はそのナトリウム塩からなる脳代謝改善剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03161442A (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10300077B2 (en) | 2016-09-12 | 2019-05-28 | Steven Hoffman | Compositions and methods for treating dementia |
| PH12021552866A1 (en) | 2019-05-14 | 2022-11-07 | Tyme Inc | Compositions and methods for treating cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
-
1989
- 1989-11-21 JP JP30359889A patent/JPH03161442A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03161442A (ja) | 1991-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4143130A (en) | Method for treating kidney stones | |
| FR2508798A1 (fr) | Derives anthraquinoniques pour le traitement des arthrites | |
| RO108220B1 (ro) | Preparate farmaceutice,pentru combaterea carceilor musculari si procedeu de obtinere a acestora | |
| DE2308826B2 (de) | Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel | |
| JPH0541605B2 (enrdf_load_stackoverflow) | ||
| US4156721A (en) | Method of production of active substance of an antinephrolithiatic, the antinephrolithiatic, and its application for therapy of the nephrolithiasis | |
| JPH0541604B2 (enrdf_load_stackoverflow) | ||
| JPS6355489B2 (enrdf_load_stackoverflow) | ||
| Anderson et al. | The treatment of pulmonary edema in the absence of renal function: a role for sorbitol and furosemide | |
| DK145420B (da) | Analogifremgangsmaade til fremstilling af alfa-methyl-5-benzoyl-2-thiophenacetatet af tromethamin | |
| DE69019431T2 (de) | Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions. | |
| DE2640707B2 (de) | Verfahren zur Herstellung von Arzneipräparaten mit einem Gehalt an von im Darm resorbierbaren Protein und Peptidlösungen | |
| Dorland | The American Illustrated Medical Dictionary: A New and Complete Dictionary of the Terms Used in Medicine, Surgery, Dentistry, Pharmacy, Chemistry, and the Kindred Branches, with Their Pronunciation, Derivation and Definition | |
| JPH02500671A (ja) | 抗乾癬医薬組成物の調製方法 | |
| DE69018903T2 (de) | Verwendung von Prostansäurederivaten zur Herstellung von Arzneimitteln zur Verbesserung der Ausscheidung von Nichtprotein in die Därme. | |
| EP0187653B1 (de) | Galleersetzende, die Fettverdauung fördernde Arzneimittelpräparate und Verfahren zu ihrer Herstellung | |
| EP0032825A2 (en) | Stabilized solutions of dioctyl calcium sulfosuccinate in corn oil | |
| US4774257A (en) | Treatment of urinary calculi | |
| US4774258A (en) | Treatment of urinary calculi | |
| JPS58118514A (ja) | 活性成分としてコラン酸誘導体を含む胆汁分泌物質活性治療用組成物 | |
| IE44733B1 (en) | Theophylline compositions | |
| DE69831348T2 (de) | Blutcholesterinsenkung durch die in vivo fällung von gallenbestandteilen mit gruppe ii oder -iii -metallverbindungen | |
| CA1214993A (en) | Means for medicinal treatment and metaphylaxis of urate and mixed urate lithiase | |
| Schenck-Gustafsson | Quinidine-induced reduction of the biliary excretion of digoxin in patients | |
| DE1543733B2 (de) | Aluminium-bis-alpha-ip-chlorphenoxy) isobutyrat und diese Verbindung als Wirkstoffenthaltende Heilmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |